Discontinuation of flecainide and metoprolol alongside hyperkalemia management restored normal sinus rhythm and resolved acute kidney injury in a 67-year-old male with BRASH syndrome.
Case Report (n=1)
Recognition of BRASH syndrome and the synergistic effect of renal insufficiency, hyperkalemia, and AV nodal blockers is crucial to prevent recurrent symptomatic bradycardia and unnecessary interventions.
First described in 2016, BRASH syndrome is an underreported clinical entity characterized by bradycardia, renal dysfunction, atrioventricular nodal blockade (AVNB), shock, and hyperkalemia. The recognition of BRASH syndrome as a clinical entity is crucial for early and effective management. Patients with BRASH syndrome present with symptomatic bradycardia that is resistant to treatment with standard agents such as atropine. In this report, we present the case of a 67-year-old male patient who presented with symptomatic bradycardia with an ultimate diagnosis of BRASH syndrome. We also shed light on predisposing factors and challenges encountered during the management of affected patients.
Saini et al. (Mon,) conducted a case report in BRASH syndrome (n=1). Discontinuation of AV nodal blocking agents and hyperkalemia management was evaluated. Discontinuation of flecainide and metoprolol alongside hyperkalemia management restored normal sinus rhythm and resolved acute kidney injury in a 67-year-old male with BRASH syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: